China's revised drug administration law, adopted by the top legislature in August, went into effect on Dec 1, as part of the country's efforts to strengthen supervision to ensure drug safety.
State Councilor Wang Yong urged reforms on drug supervision work and innovative practices during his inspection tours to the National Institutes for Food and Drug Control and the Center for Drug Evaluation under the National Medical Products Administration on Nov 8.
A home-grown drug treating Alzheimer's disease, the first innovative drug in this area in the past 17 years globally, will be available to Chinese patients before the end of this year.
Jiao Hong, Commissioner of China’s National Medical Products Administration (NMPA), recently signed a statement of intent with Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus.
Li Li, Deputy Commissioner of the National Medical Products Administration, met with a Cuban delegation led by Miguel Angel Ramirez Ramos, outgoing Cuban ambassador to China on Oct 15.
From October 11 to 13, 2019, the 2019 ISPE-CCFDIE China Conference, jointly organized by China Center for Food and Drug International Exchange (CCFDIE), NMPA Center for Food and Drug Inspection and the International Society for Pharmaceutical Engineering (ISPE), was successfully held in Nanchang.